# NeuCyte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neucyte

- Industry: Pharmaceuticals
- Headquarters: Sunnyvale, US
- Website: http://www.neucyte.com
- Total disclosed funding: $6.7M
- Latest round: Series A (May 8, 2018)
- Investors on record: 2

## About

NeuCyte, Inc. is a biotechnology company focused on advancing central nervous system (CNS) drug discovery through innovative solutions and proprietary technology.Founded in 2015, NeuCyte, Inc. operates out of Sunnyvale, US, and specializes in biotechnology solutions for CNS drug discovery. The company was established to develop human induced pluripotent stem cell (iPSC)-derived neurons for research applications. Daniel Haag is noted as the founder, while Tao Huang serves as the CEO. The company has engaged in a Series A funding round in May 2018, raising a total of USD 6.7 mn led by Co-Win Ventures and Leaguer Angel, which reflects its aspirations for growth within the biotechnology sector. NeuCyte has successfully completed one deal to date.NeuCyte, Inc. specializes in innovative biotechnology solutions aimed at advancing central nervous system (CNS) drug discovery. The company’s core offering is its proprietary SynFire® technology, which enables the generation of human induced pluripotent stem cell (iPSC)-derived neurons. This technology facilitates the creation of highly functional in vitro platforms for various applications including target identification and validation, efficacy testing, neurotoxicity assessment, and disease modeling. NeuCyte’s platforms utilize patient-derived and genetically engineered neural cell types to develop unique cell-based assays that model neurological and neurodegenerative disorders such as Alzheimer's disease, ALS, Epilepsy, and Fragile X Syndrome. The company serves a diverse client base that includes academic institutions, pharmaceutical companies, and research organizations involved in CNS drug discovery across North America, Europe, and Asia.The revenue model for NeuCyte is structured around partnerships and collaborations within the biotechnology sector, particularly through grant funding and contract research agreements. The company engages in B2B transactions, collaborating with institutions such as the University of California at San Francisco and KIF1A.ORG to pursue research initiatives. These collaborations involve funding arrangements where NeuCyte provides access to its proprietary technology and expertise in exchange for financial support or shared development costs. Key offerings, including the SynFire® platform and associated assay services, are positioned to attract clients in the pharmaceutical industry, enhancing their drug development pipelines through advanced in vitro models. Specific pricing structures for these products and services are not disclosed, but client agreements are expected to be tailored to the scope of the research and development efforts undertaken.NeuCyte, Inc. aims to leverage its recent funding of USD 6.7 mn from May 2018 to enhance its product offerings and market reach. The company is focused on developing new products utilizing its SynFire® technology, with plans for upcoming launches in the near future. Additionally, NeuCyte targets expansion into new markets, particularly in Europe and Asia, with a timeline to establish a stronger presence by 2023. The funding will support these initiatives, enabling the company to enhance its research capabilities and generate more advanced in vitro models that cater to the growing demand in CNS drug discovery.

## Funding rounds

- Series A, May 8, 2018, $6.7M — Co-Win Ventures, Leaguer Angel

## Investors

- Co-Win Ventures (https://capitalatlas.ai/funds/co-win-ventures) — Series A
- Leaguer Angel (https://capitalatlas.ai/funds/leaguer-angel) — Series A